
Sign up to save your podcasts
Or


Moderna pops on “robust” early results on its Covid-19 vaccine candidate, but will it pass the next big test? UnitedHealth’s 2nd-quarter profits are much higher than expected, but executives are quick to point out why investors shouldn’t get too excited. Emily Flippen analyzes those stories and shares why she’ll be watching Chinese search giant Baidu this earnings season.
By The Motley Fool4.7
16041,604 ratings
Moderna pops on “robust” early results on its Covid-19 vaccine candidate, but will it pass the next big test? UnitedHealth’s 2nd-quarter profits are much higher than expected, but executives are quick to point out why investors shouldn’t get too excited. Emily Flippen analyzes those stories and shares why she’ll be watching Chinese search giant Baidu this earnings season.

3,228 Listeners

1,498 Listeners

807 Listeners

938 Listeners

518 Listeners

1,173 Listeners

2,175 Listeners

825 Listeners

1,416 Listeners

1,044 Listeners

9,722 Listeners

196 Listeners

828 Listeners

82 Listeners

597 Listeners

989 Listeners

53 Listeners